The reiteration of a Buy rating and maintenance of a $46 price target by a reputable analyst firm like HC Wainwright & Co. is likely to instill confidence among investors and could lead to a positive short-term impact on Zentalis Pharma's stock price. The specific mention of the price target provides a clear expectation for the stock's potential upside.